Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL - Arseni, Lavinia; Sigismondo, Gianluca; Yazdanparast, Haniyeh; Hermansen, Johanne U.; Mack, Norman; Ohl, Sibylle; Kalter, Verena; ̇Iskar, Murat; Kalxdorf, Mathias; Friedel, Dennis; Rettel, Mandy; Paul, Yashna; et al. (Nature Communications, 2025)
Gesehen am 30.09.2025